reading time

SAR Share Price

Sareum Holdings has several drug candidates, primarily focused on cancer and autoimmune diseases. In 2021, the company announced positive results from preclinical studies of its selective tyrosine kinase 2 (TYK2) inhibitor, which is being developed for treating autoimmune diseases. These results demonstrated that the TYK2 inhibitor effectively reduced inflammation in animal models of rheumatoid arthritis and inflammatory bowel disease.

In addition, Sareum has entered into several strategic partnerships in recent years. In 2019, the company announced a collaboration with Hebei Medical University Biomedical Engineering Center to develop a TYK2 inhibitor for treating autoimmune diseases. In 2020, Sareum announced a licensing agreement with ProXara Biotechnology to develop its cancer drug candidate, SRA737.


SAR Share Price

The London Stock Exchange’s AIM has listed Sareum Holdings PLC under the SAR ticker. As of this post, SAR Share Price is at 90.90 GBp.

As with any publicly traded stock, the value of SAR can fluctuate based on various factors such as the company’s financial performance, news events, industry trends, and overall market conditions.

Investors considering investing in SAR should do their due diligence and research the company thoroughly before making any investment decisions. This includes analyzing the company’s financial statements, understanding its products and pipeline, and keeping abreast of any news or regulatory developments that could impact its operations.

Brief Background of SAR Share

Sareum Holdings PLC is a biopharmaceutical company founded in 2003 in Cambridge, UK. The company focuses on discovering and developing innovative small-molecule drugs, primarily targeting cancer and autoimmune diseases.

Sareum’s initial focus was on developing drugs that targeted kinases, a family of proteins that play a crucial role in cell signaling and are frequently implicated in cancer and other diseases. Over time, the company has expanded its research and development efforts to include other drug targets.

In 2004, Sareum went public and began trading on the London Stock Exchange’s AIM market. Since then, the company has raised additional capital through various funding rounds to support its research and development efforts.

One of Sareum’s most promising drug candidates is a selective inhibitor of the Aurora kinase enzyme, which plays a critical role in cell division and is frequently overexpressed in cancer cells. The company has also developed drug candidates that target other kinases and a class of enzymes called histone deacetylases (HDACs), which have been implicated in cancer and other diseases.

Overall, Sareum has focused on building a robust pipeline of drug candidates that have the potential to address unmet medical needs in a variety of disease areas.

Advantages of Investing in SAR Share

  1. Innovative drug pipeline. Sareum is focused on developing innovative small-molecule drugs, primarily targeting cancer and autoimmune diseases. The company’s drug candidates have the potential to address unmet medical needs and provide patients with new treatment options.
  2. Experienced management team. Sareum’s management team has extensive biopharmaceutical and drug development experience. The team has a track record of successfully developing and commercializing drugs, which could benefit the company’s prospects.
  3. Strategic partnerships. Sareum has partnered with several biopharmaceutical companies, including Sierra Oncology, Hebei Medical University Biomedical Engineering Center, and ProXara Biotechnology. These partnerships could provide the company additional resources and expertise to advance its drug development efforts.
  4. Market potential. The market for cancer and autoimmune disease treatments is large and growing, which could bode well for Sareum’s prospects if its drug candidates are successful. In addition, the company’s focus on small-molecule drugs could make its treatments more accessible and cost-effective than other therapies.

Main Competitors of SAR

The company’s main competitors may vary depending on the specific drug targets and disease areas in which it is focused, but some of the key competitors in the industry include:

  1. Large pharmaceutical companies. Large pharmaceutical companies such as Roche, Pfizer, and Novartis have significant resources and expertise in drug development, which could make them formidable competitors for Sareum. In addition, these companies have extensive pipelines of drugs in development, including cancer and autoimmune disease treatments.
  2. Biotechnology companies. Many biotechnology companies operate in cancer and autoimmune diseases, including Seattle Genetics, Incyte, and Bluebird Bio. These companies have specialized expertise in specific disease areas and may pose a competitive threat to Sareum’s drug development efforts.
  3. Other small molecule drug developers. Sareum’s focus on small-molecule drugs makes it a competitor to other companies developing similar treatments. Some examples of other small molecule drug developers include Array BioPharma, Exelixis, and Tesaro.

The Best Copytrading Platform

eToro UK
Minimum deposit 200 USD
Regulated in Europe
Trade selections Forex, Crypto, Stocks, Commodities, ETFs, Indices
  • Zero Commissions on Trades

  • CopyPortfolios/Copytrade Feature

  • Ask Experts Questions

  • Wide Range of Stocks


Sareum Holdings has also raised capital to fund its drug development efforts. In 2020, the company raised £1.9 million through a share placing, and in 2021, it raised an additional £1.9 million through a share placing and subscription.

Overall, Sareum Holdings appears to be progressing in advancing its drug pipeline, securing partnerships, and raising capital to fund its operations. However, as with any biopharmaceutical company, success is not guaranteed. The company will need to continue to demonstrate the efficacy and safety of its drug candidates in clinical trials to achieve commercial success ultimately.


FAQ: SAR Share Price

What is the historic performance of Sareum Holdings PLC stock?

According to publicly available data, the company's stock price fluctuated between a high of approximately 6 pence per share in early 2018 and a low of approximately 0.5 pence per share in early 2020. In recent years, the company has undertaken several share placings to raise capital to fund its drug development efforts, diluting existing shareholders.

Does Sareum Holdings PLC pay dividends to its stockholders?

Sareum Holdings PLC has not paid any dividends to its stockholders recently.

How much does Sareum Holdings PLC make in a year?

Sareum Holdings has not yet generated significant revenues as it primarily focuses on developing its drug pipeline.

Sareum Holdings is a pre-revenue biotechnology company, meaning it has not yet commercialized its drug candidates and does not generate significant revenue from its operations. As many small-cap biotech companies focused on drug development, Sareum's financial performance is primarily driven by investments and funding from capital raises, partnerships, and grants, which it uses to fund its research and development efforts.

Rate this post
Simon Williams
Latest posts by Simon Williams (see all)